Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.

ABSTRACT: Adequate preclinical model and model establishment procedure are required to accelerate translational research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and identified effective targeted therapies and novel resistance mechanisms using PDCs. We generated 23 PDCs from 96 malignant effusions of 77 patients with advanced lung adenocarcinoma. Clinical and experimental factors were reviewed to identify determinants for PDC establishment. PDCs were characterized by driver mutations and in vitro sensitivity to targeted therapies. Seven PDCs were analyzed by whole-exome sequencing. PDCs were established at a success rate of 24.0%. Utilizing cytological diagnosis and tumor colony formation can improve the success rate upto 48.8%. In vitro response to a ty

SUBMITTER: Kim SY 

PROVIDER: S-EPMC6934824 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature